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Abstract
Context: Levothyroxine monotherapy is the treatment of choice for hypothyroid patients because peripheral T4 to T3
conversion is believed to account for the overall tissue requirement for thyroid hormones. However, there are indirect
evidences that this may not be the case in all patients.
Objective: To evaluate in a large series of athyreotic patients whether levothyroxine monotherapy can normalize serum
thyroid hormones and thyroid-pituitary feedback.
Design: Retrospective study.
Setting: Academic hospital.
Patients: 1,811 athyreotic patients with normal TSH levels under levothyroxine monotherapy and 3,875 euthyroid controls.
Measurements: TSH, FT4 and FT3 concentrations by immunoassays.
Results: FT4 levels were significantly higher and FT3 levels were significantly lower (p,0.001 in both cases) in levothyroxine-
treated athyreotic patients than in matched euthyroid controls. Among the levothyroxine-treated patients 15.2% had lower
serum FT3 and 7.2% had higher serum FT4 compared to euthyroid controls. A wide range of FT3/FT4 ratios indicated a
major heterogeneity in the peripheral T3 production capacity in different individuals. The correlation between thyroid
hormones and serum TSH levels indicated an abnormal feedback mechanism in levothyroxine-treated patients.
Conclusions: Athyreotic patients have a highly heterogeneous T3 production capacity from orally administered
levothyroxine. More than 20% of these patients, despite normal TSH levels, do not maintain FT3 or FT4 values in the
reference range, reflecting the inadequacy of peripheral deiodination to compensate for the absent T3 secretion. The long-
term effects of chronic tissue exposure to abnormal T3/T4 ratio are unknown but a sensitive marker of target organ
response to thyroid hormones (serum TSH) suggests that this condition causes an abnormal pituitary response. A more
physiological treatment than levothyroxine monotherapy may be required in some hypothyroid patients.
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Introduction
The elective treatment for hypothyroid patients requiring
replacement therapy is oral administration of synthetic levothy-
roxine. Although the normal thyroid gland secretes both T4 and
T3, the peripheral conversion of ingested levothyroxine into T3 is
believed to provide the overall required amount of thyroid
hormones necessary to reach the euthyroid state, as indicated by
serum TSH levels within the normal range.
Over the years, it has been recognized that some hypothyroid
patients do not obtain a condition of well-being under levothy-
roxine monotherapy and prefer T3–T4 combined treatment [1,2].
Moreover, to achieve normal serum TSH levels, the administered
levothyroxine dose must be sufficient enough to raise serum free
T4 (FT4) concentration to the upper normal range [3,4].
These observations suggest that some levothyroxine-treated
hypothyroid patients may have an insufficient T3 production and
a reduced T3/T4 ratio. Their peripheral tissues may be exposed
to an imbalanced availability of circulating thyroid hormones. The
consequences of this condition are not clear. Tissues take up
iodothyronines by surface transporters and deiodinate the pre-
hormone T4 to the active hormone T3. Different tissues, however,
express different machinery (in terms of both quality and quantity
of transporters and deiodinases) for producing intracellular T3 and
differ in their ability to compensate for an abnormal T3/T4
availability [5,6]. Because of tissue heterogeneity, pituitary
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and, therefore, in some instances serum TSH may not be an
appropriate indicator of peripheral tissue euthyroidism [7,8,9].
This has been demonstrated in thyroidectomized rats that, when
infused with levothyroxine alone, do not reach euthyroidism at all
tissue level [5]. Although similar studies have not been carried out
in humans, it is possible that the unsatisfactory health condition of
some hypothyroid patients, even when well compensated in terms
of TSH serum levels [10,11], might be due to insufficient T3
availability in one or more peripheral tissues.
Athyreotic patients do not secrete endogenous thyroid hor-
mones and all circulating T4 and T3 originate from replacement
treatment with levothyroxine. These patients, therefore, are an
ideal model to study peripheral tissues’ capacity to produce the
biologically active hormone T3 from the exogenous prehormone
T4.
We evaluated FT4 and free T3 (FT3) serum levels in a large
series of athyreotic patients under oral levothyroxine monother-
apy. All patients were euthyroid on the basis of their TSH serum
level within the normal range. Compared to euthyroid controls,
one fifth of the athyreotic patients treated with levothyroxine
monotherapy had abnormal values of either FT3 or FT4.
Moreover, an abnormal thyroid-pituitary feedback was observed




Serum TSH, FT4 and FT3 values were retrospectively analyzed
in a continuous series of 3,473 athyreotic patients who were all
followed at our Thyroid Clinic (University of Catania, Garibaldi-
Nesima Hospital, Catania, Italy) from 2000–2007, after undergo-
ing total thyroidectomy for thyroid cancer. All were treated with
levothyroxine monotherapy at a stable dosage since at least 3
months prior to our examination.
Of these patients, those under ‘‘suppressive’’ levothyroxine
treatment (n=1,662, TSH,0.4 mU/L) because of their thyroid
cancer risk category, were excluded. Patients with normal (0.4–
4.0 mU/L) serum TSH levels under levothyroxine monotherapy
were included (n=1,881) and, out of them, 598 (33%) had also
been treated with
131iodine to ablate residual thyroid tissue.
Patients were subdivided according to gender (F=1,530 and
M=281) and age (1,298,60 y and 513$60 y). All patients were
disease-free from thyroid cancer as judged by serum thyroglobulin
levels (#0.5 ng/ml after levothyroxine treatment withdrawal) and
had a negative ultrasound neck examination and a negative total
body scan, if required. All were treated with a levothyroxine
dosage adequate to maintain TSH serum concentrations within
the normal range (0.4–4.0 mU/L). Levothyroxine was always
recommended to be ingested in the morning, with water and in a
fasting state, and hormones were measured from a serum sample
obtained in the morning, before levothyroxine ingestion. When
more than one set of measurements was available for the same
patient, the most recent sample was chosen.
Serum TSH, FT4 and FT3 values were retrospectively analyzed
also in a continuous series of 3,875 euthyroid subjects, all resident
in areas of sufficient iodine intake [12]. These subjects were
referred to our Thyroid Clinic in the same time period because of
a non-functioning benign thyroid nodule ,20 mm diameter and
they showed no clinical or laboratory sign of altered thyroid
function. Clinically euthyroid subjects with serum TSH,0.4 or
.4.0 mU/L were excluded under suspicion of subclinical hyper-
or hypo-thyroidism. Subjects positive for anti-TPO and/or anti-
Tg antibodies and/or with hyperechogenicity or pseudo-nodular
pattern at thyroid ultrasound examination were also excluded. As
for athyreotic patients, also subjects in this group were subdivided
by gender (F=3,224, M=651) and age (2,927,60 y and
948$60 y). None of these control subjects had ever been treated
with thyroid hormones or antithyroid drugs.
In both groups, patients with clinically significant organ diseases
(renal failure and severe liver disease) or recent (less than 6 months)
major surgery or illness or with familial thyroid disease or being
treated with drugs known to interfere with thyroid function or
thyroid hormone metabolism were excluded. In particular,
patients using amiodarone, propranolol, steroids or with recent
(less than one year) use of iodinated contrast material were
excluded to avoid potential interferences with deiodinase activity.
The study was approved by the local Ethics Committee.
Hormone measurements
All hormone measurements were determined in our Hospital’s
central laboratory. Serum FT3, FT4 and TSH levels were
measured by automated microparticle enzyme immunoassays
(Abbott AxSYM-MEIA, Abbott Park, IL, USA) with inter-assay
coefficients of variation of less than 10% over the analytical ranges
of 1.7–46.0 pmol/L for FT3, 5.15–77.0 pmol/L for FT4 and
0.03–10.0 mU/L, for TSH. The within-run and between–run
precisions for the FT3, FT4 and TSH assays showed coefficients of
variation ,5%.
Statistical Analysis
The TSH serum value distribution was non-Gaussian, with a
skewness toward higher values. Also, for FT4 and FT3 serum
values the normal distribution assumptions were not satisfied using
the D’Agostino-Pearson test. Therefore, non-parametric tests were
used and results were reported as a median value and an
interquartile range (IQR, 25
th–75
th quartiles). The Mann-Whitney
non-parametric test for unpaired values was used to determine
statistical significance. To calculate linear regression coefficients,
TSH data were log transformed to normalize the skewed
distribution. Data were analyzed with the Prism software package
(GraphPad, USA). Differences between groups, after adjusting for
several covariates, were evaluated by the covariance analysis
(ANCOVA) test using SPSS (version 15.0; SPSS, Chicago, IL,
USA).
Results
TSH, FT4 and FT3 serum values in euthyroid controls
In our series of 3,875 euthyroid adults, median serum TSH
value was 1.40 mU/L (interquartile range, IQR=0.90–2.10);
median FT4 value was 13.8 pmoles/L (IQR=12.0–15.4); and
median FT3 value was 4.47 pmoles/L (IQR=3.85–4.94)
(Table 1). In this euthyroid population the normal range (2.5–
97.5 percentiles) was 9.0–20.6 pmoles/L for FT4 and 2.9–
6.0 pmoles/L for FT3. The median individual FT3/FT4 ratios
was 0.32 (IQR=0.27–0.37) (Figure 1).
Hormone values were influenced by both gender and age. FT3
values were lower and TSH values were higher in females
compared to males of the corresponding age range (Table 1). Also
FT4 values in women younger than 60 yr were lower than those
observed in men and, in this group of women, median FT4 value
was significantly lower than that of older women and of men in
both age groups (P,0.001 in both cases) (Table 1). These
observations are in agreement with previous data on the effects of
age and gender differences on serum free thyroid hormone values
[13,14]. Therefore, in the euthyroid controls the FT3/FT4 ratio
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than 60 relative to older subjects of the same gender (Table 1).
Using a linear regression analysis model, in the euthyroid controls
TSH serum values were inversely correlated with the serum FT4
values (r
2=0.0087, slope 21.1, P,0.0001) but not with the FT3
serum values (r
2=0.0001, slope 20.0029, P=0.536) (Figure 2).
TSH, FT4 and FT3 serum values in athyreotic patients
under levothyroxine monotherapy
In the 1,811 athyreotic patients with normal serum TSH values
(0.4–4.0 mU/L) under levothyroxine monotherapy, the median
serum TSH was 1.20 mU/L (IQR=0.69–2.20), the median
serum FT4 value was 15.4 pmoles/L (IQR=14.2–17.6,
P,0.001 compared to euthyroid controls) and the median serum
FT3 value was 3.70 pmoles/L (IQR=3.73–4.31, P,0.001
relative to controls). The median individual FT3/FT4 ratio was
0.24 (0.20–0.28, P,0.001) (Table 1). These significant differences
were observed also when patients were subdivided according to
age and gender and then compared to age and gender matched
controls.
In levothyroxine–treated athyreotic patients, the effect of age
and gender on hormone levels was different from euthyroid
controls. As expected, in athyreotic patients the FT4 serum levels,
which are dependent on the ingested levothyroxine, were similar
in all age and gender groups. In contrast, the FT3 values, which
depend on peripheral deiodination of the ingested levothyroxine,
were significantly higher in males younger than 60 yrs compared
to older males and to females, as observed in the euthyroid
controls (Table 1).
Among the athyreotic patients, despite normal serum TSH
levels, 15.2% had serum FT3 levels lower than the normal range
and 7.2% had FT4 levels higher than the normal range (Figure 1).
The percentage of athyreotic patients with FT3 serum levels lower
than the normal range was 8.6% in males and 16.4% in females
(P=0.044). The percentage of FT3 serum values lower than the
normal range was also lower in patients younger than 60 yrs
(14.3%) compared to the older patients (17.4%) but this difference
was not statistically significant. Finally, 29.6% of the levothyrox-
ine-treated athyreotic patients had FT3/FT4 ratios lower than the
normal range (,2.5 percentile in the euthyroid controls) (Figure 1).
The percentage of patients with an abnormally low FT3/FT4
ratio progressively increased with increasing levothyroxine dose,
reaching 37.7% in the 319 patients treated with .2.0 mg/kg/d of
levothyroxine (Figure 3).
Table 1. TSH, FT4, FT3 levels in studied subjects by age and gender.
F/M no. Age (yrs) TSH (mU/L) FT4 (pmol/L) FT3 (pmol/L) FT3/FT4 ratio L-T4 (mg/Kg/d)
Euthyroid controls 4.9:1 3875 49 (37–61) 1.40 (0.90–
2.10)
13.8 (12.0–15.4) 4.47 (3.85–4.94) 0.32 (0.27–0.37)
Females all 3224 49 (37–61) 1.40 (0.90–
2.10)
13.6 (11.8–15.4) 4.40 (3.85–4.93) 0.32 (0.27–0.37)
#60 yr 2457 45 (36–53) 1.41 (0.90–
2.17)
13.4 (11.6–15.4){ 4.44 (3.85–4.93) 0.32 (0.27–0.37)
.60 yr 767 68 (64–72) 1.29 (0.80–
1.96)
14.2 (12.2–15.4) 4.31 (3.85–4.91) 0.30 (0.26–0.36)1
Males all 651 51 (35–64) 1.29 (0.80–
1.94)
14.2 (12.5–15.9) 4.62 (4.16–5.30) 0.33 (0.28–0.39){
#60 yr 470 45 (37–52) 1.30 (0.85–
2.00)*
14.2 (12.5–16.0) 4.79 (4.24–5.40)* 0.33 (0.28–0.39)
.60 yr 181 68 (64–73) 1.20 (0.75–
1.80)*
14.2 (12.4–15.6) 4.47 (4.00–5.08)* 0.31 (0.26–0.36)1
L-T4 treated pts 5.4:1 1811 51 (42–61) 1.20 (0.69–
2.20)I
15.4 (14.2–17.6)I 3.70 (3.23–4.31)I 0.24 (0.20–0.28)I 1.59 (1.36–1.86)
Females all 1530 52 (42–61) 1.20 (0.69–
2.20)
15.4 (14.2–17.5) 3.70 (3.23–4.29) 0.24 (0.20–0.27) 1.59 (1.34–1.84)
#60 yr 1088 46 (39–53) 1.12 (0.60–
2.10)
15.4 (14.2–17.0) 3.70 (3.23–4.31) 0.24 (0.21–0.28) 1.64 (1.40–1.93)
.60 yr 442 66 (63–72) 1.20 (0.70–
2.31)1
15.4 (14.2–18.0) 3.70 (3.16–4.16) 0.23 (0.20–0.26)1 1.43 (1.23–1.67)
Males all 281 48 (35–64) 1.20 (0.69–
2.40)
15.4 (14.2–18.0) 3.87 (3.47–4.40) 0.25 (0.21–0.28){ 1.63 (1.41–1.92)
#60 yr 210 45 (36–52) 1.10 (0.64–
2.40)
15.4 (14.2–18.0) 4.00 (3.54–4.47)" 0.25 (0.21–0.29) 1.73 (1.47–1.98)
.60 yr 71 67 (63–73) 1.40 (0.80–
2.60)
15.5 (14.2–17.0) 3.70 (3.39–4.14)1 0.24 (0.20–0.27) 1.43 (1.37–1.67)
Values indicate median and interquartile ranges (IQR). FT3=free triiodothyronine; FT4=free thyroxine; TSH=thyroid-stimulating hormone; L-T4=levothyroxine.
*p,0.001: males vs. females in the same age groups.
{p,0.001: females#60 yr vs. females.60 yr and males, both age groups.
{p=0.027: males vs. females.
1p,0.001: #60 yr vs. .60 yr of the same gender.
Ip,0.001: L-T4 treated athyreotic patients vs. euthyroid controls.
"p,0.001: males #60 yr vs. females in the same age range.
doi:10.1371/journal.pone.0022552.t001
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When the 1,811 levothyroxine-treated athyreotic patients with
normal TSH serum value were subdivided in groups according to
their TSH level and then matched to euthyroid subjects with
comparable TSH levels, the median FT4 serum level was
significantly higher and the median FT3 serum level was
significantly lower in each levothyroxine-treated group compared
to TSH-matched euthyroid controls (Table 2). These differences
remained significant after the data were adjusted for age, gender
and TSH values (P,0.001, ANCOVA test). At a similar median
serum FT4 level the median serum TSH value was much lower in
the euthyroid controls than in the levothyroxine–treated patients
(Table 2). Moreover, the linear regression analysis (Figure 2)
between TSH and FT4 serum values was much steeper in
levothyroxine-treated patients who, therefore, required a signifi-
cantly greater FT4 serum change to obtain the same feed-back
effect on pituitary TSH-secreting cells. This difference may be
explained by the different FT3 levels in the two conditions, with
values significantly lower in the levothyroxine-treated athyreotic
patients (Table 2). When serum FT4 levels decreased, euthyroid
controls partially compensated by maintaining a nearly constant
FT3 serum level (Figure 2), a likely consequence of increased T3
de novo synthesis in the thyroid. In contrast, in levothyroxine-
Figure 1. Free thyroid hormones and FT3/FT4 ratio frequency
distribution. FT3 and FT4 serum levels and FT3/FT4 ratio distribution
in 1,811 athyreotic patients under levothyroxine (L-T4) monotherapy.
Shaded areas indicate the normal range (2.5–97.5 percentiles)
calculated in 3,875 euthyroid controls. Vertical dotted lines indicate
the median of the normal values. Percentages indicate the patients with
values under or above the normal values.
doi:10.1371/journal.pone.0022552.g001
Figure 2. Correlation between TSH and free thyroid hormones
in euthyroid controls and in athyreotic patients. The correlation
between TSH serum levels (log values) and FT3 and FT4 serum levels in
3,875 euthyroid controls (solid lines) and 1,811 athyreotic patients
under levothyroxine monotherapy (dotted lines). The linear regression
equations between FT4 and log TSH levels in the euthyroid controls and
the levothyroxine (L-T4)-treated patients were y=14.021.1x (95%: slope
21.4 to 20.74) and y=16.122.01x (95% CI: slope 22.48 to 21.53),
respectively. The same curve fitting analysis was used between FT3 and
log-TSH levels and resulted in the following: y=4.420.029x (95% CI:
slope 20.128 to 0.063) for euthyroid controls and y=3.8420.575x (95%
CI: slope 20.697 to 20.453) for L-T4-treated patients. R square and P
values are reported in the graph.
doi:10.1371/journal.pone.0022552.g002
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level decrease but the magnitude of serum TSH change was
smaller suggesting a less sensitive response of thyrotropic cells to
thyroid hormones.
Discussion
In a very large series of athyreotic patients we observe that, to
obtain euthyroidism as indicated by TSH normalization, FT4
values must be significantly higher than in euthyroid controls.
Conversely, in spite of the increased FT4 levels, FT3 serum values
are significantly lower than in normal subjects, suggesting that
peripheral T4 to T3 conversion may not be sufficient to maintain a
normal FT3/FT4 ratio under levothyroxine monotherapy. The
decreased FT3/FT4 ratio is more marked in a subset of patients
(approximately one third in our study) that do not reach a serum
FT3/FT4 ratio within the reference range observed in euthyroid
controls (Figure 1). These patients, therefore, live in a chronic
condition of abnormal thyroid hormone availability for the
peripheral tissues, even if the administered levothyroxine dose is
able to maintain the serum TSH within the normal range. This
condition is more frequent in female and aged patients, indicating
a significant gender and age influence on the individual capacity to
produce T3 from exogenous levothyroxine.
These abnormalities have already been reported [3,4,15] but
their relevance has been minimized in the absence of clear
evidence that they may have clinical consequences. Therefore,
based on the evidence that (i) all hypothyroid patients can reach
normal TSH serum levels adjusting the levothyroxine dose; (ii) that
most (although not all) patients can maintain a condition of
Figure 3. FT3/FT4 ratio in levothyroxine-treated athyreotic patients at different daily dose. Median FT3/FT4 ratio in levothyroxine (L-T4)
treated athyreotic patients with respect to the administered daily dose of L-T4. The median and interquartile range in the euthyroid controls are
indicated by the shaded area. The number of patients with a FT3/FT4 ratio lower than the 2.5 percentile of the euthyroid controls is indicated in the
right panel.
doi:10.1371/journal.pone.0022552.g003




n. TSH (mU/L) FT4 (pmol/L) FT3 (pmol/L) FT3/FT4 ratio
0.40–1.00 1306 0.70 (0.57–0.90) 14.2 (12.5–15.7) 4.47 (3.85–5.00) 0.31 (0.27–0.36)
1.01–1.50 878 1.30 (1.16–1.40) 13.9 (12.1–15.4) 4.34 (3.85–4.93) 0.31 (0.27–0.37)
1.51–2.00 625 1.79 (1.62–1.90) 13.8 (12.0–15.4) 4.47 (3.85–4.93) 0.31 (0.27–0.37)
2.01–2.50 402 2.26 (2.11–2.40) 13.4 (11.6–15.4) 4.47 (3.85–4.94) 0.32 (0.27–0.37)
2.51–4.00 664 3.10 (2.70–3.70) 12.9 (11.6–15.0) 4.47 (3.85–5.00) 0.33 (0.28–0.39)
Athyreotic patients (n=1811)
n. TSH (mU/L) FT4 (pmol/L) FT3 (pmol/L) FT3/FT4 ratio
0.40–1.00 793 0.60 (0.47–0.80) 15.7 (14.2–18.0)* 3.96 (3.39–4.47)* 0.24 (0.21–0.27)*
1.01–1.50 326 1.20 (1.12–1.40) 16.2 (14.2–18.0)* 3.85 (3.39–4.37)* 0.24 (0.20–0.27)*
1.51–2.00 183 1.80 (1.67–1.90) 15.4 (14.2–16.7)* 3.65 (3.13–4.15)* 0.23 (0.20–0.28)*
2.01–2.50 135 2.30 (2.16–2.38) 14.9 (13.3–17.6)* 3.60 (3.13–4.04)* 0.24 (0.20–0.28)*
2.51–4.00 374 3.32 (2.90–4.07) 14.2 (12.9–15.4)* 3.39 (2.96–3.90)* 0.23 (0.20–0.28)*
Values indicate median and interquartile ranges (IQR). FT3=free triiodothyronine; FT4=free thyroxine; TSH=thyroid-stimulating hormone; L-T4=levothyroxine.
*p,0.001: L-T4-treated athyreotic patients vs. euthyroid controls with similar serum TSH levels.
doi:10.1371/journal.pone.0022552.t002
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in many studies a short period of T4-T3 combination therapy has
not caused a significant improvement in a variety of symptoms, the
conclusion has been drown that levothyroxine monotherapy must
be the standard treatment for all hypothyroid patients [16]. It
should be underlined, however, that no long-term study is
available to assess that the abnormal circulating thyroid hormone
ratio has no adverse effect and that even short-term studies
indicate that some hypothyroid patients do not reach a condition
of well-being and emotional satisfaction under levothyroxine
monotherapy [17]. Their condition may ameliorate under a
combined T4-T3 treatment [1,18,19,20].
Studying a sufficiently large series of thyroidectomized patients
without residual thyroid tissue we now observe that, despite
normal serum TSH, under levothyroxine monotherapy approx-
imately one fifth of them has either FT3 or FT4 serum levels
outside the reference range in euthyroid controls. Moreover, also
among levothyroxine treated patients with normal circulating
hormones, normality can be questioned in same cases. In the study
by Jonklaas et al [21], aimed at demonstrating that normal T3
serum values can be obtained in all athyreotic patients under
levothyroxine replacement therapy, the normal T3 value, similar
to the pre-thyroidectomy value, is an average value that includes
values changed more than 30% in respect to the previous T3
serum levels and is obtained at the expenses of an average 50%
increase of TSH and 30% increase of FT4. Patients that, in spite of
having hormone values in the normal range show such marked
changes in their TSH and thyroid hormones pre-surgery values
can be considered truly euthyroid [22]? Individuals with changes
of similar magnitude in biologic parameters like glycemia or
hearth rate would not be considered normal because, although no
clinical signs or symptoms are present, deleterious consequences
will appear in the long run.
The major source of T3 within peripheral tissues comes from
the circulating T3 pool and the variable portion coming from
locally deiodinated T4 within each tissue might be not adequate
according to animal experiments [5]. The long-term effect of this
abnormal condition are unknown and the proof of concept that no
benefit can derive from combined T4/T3 treatment cannot be
affirmed on the basis of short-term studies.
Analyzing the correlation between TSH and thyroid hormones
serum levels in a large series of athyreotic patients under
levothyroxine monotherapy, we observe that in these patients
the pituitary response is significantly different from normal, being
the pituitary feedback much less sensitive than in euthyroid
controls (Figure 2). This evidence indicates that the effect of
thyroid hormones at pituitary level is altered in athyreotic patients
under levothyroxine monotherapy. A practical consequence of this
finding is that normalization of serum TSH cannot be always
considered an appropriate marker of euthyroidism in levothyrox-
ine-treated patients.
Athyreotic individuals show a relevant heterogeneity in their
capacity to deiodinate exogenous levothyroxine to T3 as indicated
by the variability of FT3 serum concentrations in patients with
similar FT4 levels. While most patients under levothyroxine
monotherapy will reach normal TSH serum levels, a normal FT3/
FT4 ratio and also full improvement of signs and symptoms, a
subset of patients is unable to convert the ingested levothyroxine
into an adequate amount of T3. This may happen for a variety of
reasons, including congenital or acquired deficiency of deiodinase
function [23,24,25] and also abnormal thyroid hormone metab-
olism independent from deiodination [26]. Whether these patients
are the ones that do not reach well-being under levothyroxine
monotherapy and could benefit from a combined, more
physiological T4/T3 treatment cannot be inferred from our study
that has not measured the well-being state or the level of
satisfaction in these patients. Our study has also the limitations
inherent to retrospective observational studies, in which the
interference of unrecognized confounders cannot be excluded in
the comparison between studied and control groups. Finally, the
lack of measurements of tissue deiodinases and of thyroid hormone
metabolites (like reverse triiodothyronine) leave to speculation the
mechanisms and the metabolic pathways involved in the
variability of the FT3/FT4 ratio in L-thyroxine treated patients.
he insufficient T3 peripheral production cannot be appropri-
ately corrected by increasing levothyroxine dose because the
inhibitory effect of elevated T4 on type II deiodinase [27,28] will
end up increasing the imbalance of the circulating FT3/FT4 ratio
(Figure 3).
In conclusion, athyreotic patients treated with levothyroxine
monotherapy show a highly heterogeneous capacity of T3
production and about one fifth of those, despite normal TSH
levels, do not maintain FT3 or FT4 values within the reference
range. A reduced thyrotropic cells sensitivity to thyroid hormones
is also present in levothyroxine-treated athyreotic patients. These
observations do not allow to take for granted the conclusions,
drawn from short-term studies, that levothyroxine monotherapy is
adequate for all hypothyroid patients [16], considering that even
subtle abnormalities might have important consequences when
lasting for many years or decades. The question whether a
subgroup of hypothyroid patients requires a more physiological
treatment is still not answered and requires further studies
[29,30,31].
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